newsfilter
← Latest News
Business Wire·

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) MorphoSys U.S. Inc., a fully owned subsidiary